BACKGROUND: The diversity of individuals at risk for Trypanosoma cruzi infection in the United States poses challenges for diagnosis. We evaluated the diagnostic accuracy of Food and Drug Administration (FDA)-cleared tests in the Washington Metropolitan area (WMA). METHODS: In total, 1514 individuals were evaluated (1078 from Mexico, Central and northern South America [TcI-predominant areas], and 436 from southern South America [TcII/V/VI-predominant areas]). Optical density (OD) values from the Hemagen EIA and Chagatest v.3 Wiener, and categorical results of the IgG-TESA-blot (Western blot with trypomastigote excretory-secretory antigen), and the Chagas detect plus (CDP), as well as information of area of origin were used to determine T. cruzi serostatus using latent class analysis. RESULTS: We detected 2 latent class (LC) of seropositives with low (LC1) and high (LC2) antibody levels. A significantly lower number of seropositives were detected by the Wiener, IgG-TESA-blot, and CDP in LC1 (60.6%, P < .001, 93.1%, P = .014, and 84.9%, P = .002, respectively) as compared to LC2 (100%, 100%, and 98.2%, respectively). LC1 was the main type of seropositives in TcI-predominant areas, representing 65.0% of all seropositives as opposed to 22.8% in TcII/V/VI-predominant areas. The highest sensitivity was observed for the Hemagen (100%, 95% confidence interval [CI]: 96.2-100.0), but this test has a low specificity (90.4%, 95% CI: 88.7-91.9). The best balance between positive (90.9%, 95% CI: 83.5-95.1), and negative (99.9%, 95% CI: 99.4-99.9) predictive values was obtained with the Wiener. CONCLUSIONS: Deficiencies in current FDA-cleared assays were observed. Low antibody levels are the main type of seropositives in individuals from TcI-predominant areas, the most frequent immigrant group in the United States.
BACKGROUND: The diversity of individuals at risk for Trypanosoma cruzi infection in the United States poses challenges for diagnosis. We evaluated the diagnostic accuracy of Food and Drug Administration (FDA)-cleared tests in the Washington Metropolitan area (WMA). METHODS: In total, 1514 individuals were evaluated (1078 from Mexico, Central and northern South America [TcI-predominant areas], and 436 from southern South America [TcII/V/VI-predominant areas]). Optical density (OD) values from the Hemagen EIA and Chagatest v.3 Wiener, and categorical results of the IgG-TESA-blot (Western blot with trypomastigote excretory-secretory antigen), and the Chagas detect plus (CDP), as well as information of area of origin were used to determine T. cruzi serostatus using latent class analysis. RESULTS: We detected 2 latent class (LC) of seropositives with low (LC1) and high (LC2) antibody levels. A significantly lower number of seropositives were detected by the Wiener, IgG-TESA-blot, and CDP in LC1 (60.6%, P < .001, 93.1%, P = .014, and 84.9%, P = .002, respectively) as compared to LC2 (100%, 100%, and 98.2%, respectively). LC1 was the main type of seropositives in TcI-predominant areas, representing 65.0% of all seropositives as opposed to 22.8% in TcII/V/VI-predominant areas. The highest sensitivity was observed for the Hemagen (100%, 95% confidence interval [CI]: 96.2-100.0), but this test has a low specificity (90.4%, 95% CI: 88.7-91.9). The best balance between positive (90.9%, 95% CI: 83.5-95.1), and negative (99.9%, 95% CI: 99.4-99.9) predictive values was obtained with the Wiener. CONCLUSIONS: Deficiencies in current FDA-cleared assays were observed. Low antibody levels are the main type of seropositives in individuals from TcI-predominant areas, the most frequent immigrant group in the United States.
Authors: Marcia M Otani; Elizabeth Vinelli; Louis V Kirchhoff; Ana del Pozo; Anita Sands; Gaby Vercauteren; Ester C Sabino Journal: Transfusion Date: 2009-03-05 Impact factor: 3.157
Authors: Neida K Mita-Mendoza; Elizabeth McMahon; Aileen Kenneson; Arturo Barbachano-Guerrero; Efrain Beltran-Ayala; Cinthya Cueva; Christine A King; Christina D Lupone; Yagahira E Castro-Sesquen; Robert H Gilman; Timothy P Endy; Anna M Stewart-Ibarra Journal: Am J Trop Med Hyg Date: 2018-10-18 Impact factor: 2.345
Authors: Yanina Sguassero; Cristina B Cuesta; Karen N Roberts; Elizabeth Hicks; Daniel Comandé; Agustín Ciapponi; Sergio Sosa-Estani Journal: PLoS One Date: 2015-10-05 Impact factor: 3.240
Authors: Maykon Tavares de Oliveira; Elena Sulleiro; Aroa Silgado Gimenez; Marta de Lana; Bianca Zingales; João Santana da Silva; J Antônio Marin-Neto; Israel Molina Journal: PLoS Negl Trop Dis Date: 2020-06-04
Authors: Jeffrey D Whitman; Christina A Bulman; Emma L Gunderson; Amanda M Irish; Rebecca L Townsend; Susan L Stramer; Judy A Sakanari; Caryn Bern Journal: J Clin Microbiol Date: 2019-11-22 Impact factor: 5.948
Authors: Colin J Forsyth; Jennifer Manne-Goehler; Caryn Bern; Jeffrey Whitman; Natasha S Hochberg; Morven Edwards; Rachel Marcus; Norman L Beatty; Yagahira E Castro-Sesquen; Christina Coyle; Paula Stigler Granados; Davidson Hamer; James H Maguire; Robert H Gilman; Sheba Meymandi Journal: J Infect Dis Date: 2022-05-04 Impact factor: 7.759